Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study
Abstract Background Schizophrenia is a severe psychiatric disorder. Poor medical adherence increases relapse rate. Long-acting injection of antipsychotic agent is developed for improving medical adherence. In this study, we examined the effect of paliperidone long-acting injection (PLAI) treatment i...
Main Authors: | Hsue-Wei Chan, Chin-Yu Huang, Yung-Chieh Yen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12888-021-03513-7 |
Similar Items
-
Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
by: Amber N. Edinoff, et al.
Published: (2021-09-01) -
Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
by: García-Carmona JA, et al.
Published: (2023-09-01) -
Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
by: Emsley R, et al.
Published: (2018-01-01) -
Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
by: M. Markovic
Published: (2022-06-01) -
Alternative initiation regimen of paliperidone palmitate long-acting injectable
by: I.E. Menendez Gil, et al.
Published: (2022-06-01)